Home / Business and Economy / STAAR Surgical Surpasses Expectations Amid Market Caution
STAAR Surgical Surpasses Expectations Amid Market Caution
17 Aug
Summary
- STAAR Surgical reported Q2 sales of $93.54 million, an 111% year-on-year increase.
- The company's non-GAAP profit exceeded analyst estimates by 9.7%.
- Strong EVO Plus adoption in China fueled the company's performance.
STAAR Surgical reported Q2 CY2026 results that surpassed market revenue expectations, with sales climbing to $93.54 million, an impressive 111% increase from the previous year. The company's non-GAAP profit of $0.25 per share also exceeded analysts' consensus estimates by 9.7%.
Management attributed the strong quarter to significant adoption of EVO Plus in China and continued market share gains from laser-based competitors. Consistent double-digit growth was also noted outside of China, particularly in the U.S. and EMEA regions. The company plans to focus on innovation, expanding its product portfolio beyond EVO lenses, and investing in R&D.
Despite these positive financial results, the market reacted negatively, potentially due to investor caution regarding the sustainability of the rapid growth. Management acknowledged uneven market conditions and headwinds from tariffs and currency fluctuations, particularly in Asia, but remains focused on revenue growth, profitability, and innovation.
